Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04192513
Other study ID # DBI-203
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 20, 2019
Est. completion date June 30, 2020

Study information

Verified date July 2020
Source DermBiont, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs. Placebo in Adults with Atopic Dermatitis (AD).


Description:

A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs. Placebo in Adults with Atopic Dermatitis and to determine the antibacterial effect of a single application of DBI-001 Gel on the abundance of S. aureus. Tolerability will be evaluated through assessment of disease state severity and signs and symptoms of local tolerability (pain / burning / stinging, pruritus, erythema, edema, and scabbing / crusting) and review of adverse events. Any local skin reaction that requires use of a concomitant therapy or study discontinuation will be reported.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date June 30, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must meet all of the following criteria to be included in the study: 1. Ability to understand, agree to, and sign the study Informed Consent. If the patient is unable to provide consent for him/herself, the patient's legally authorized representative may provide written consent. 2. A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of subject's individually identifiable health information. 3. Male or Female Subjects of any race 18 years of age and older. 4. Physician diagnosed clinically stable Atopic Dermatitis according to the criteria of Hanifin and Rajka affecting =25% of total BSA with comparable bilateral antecubital or popliteal lesions. Each lesion must have an ADSI =6 with a difference between the lesions of =1. It will be in the opinion of the Investigator whether the lesions are clinically stable. 5. Moderate to heavy growth of S. aureus based on culture at the time of screening. 6. Willingness to discontinue use of other Atopic Dermatitis treatment for the duration of the study unless specifically permitted by the Investigator. 7. Women of child-bearing potential must: - Have negative urine pregnancy tests prior to study treatment to rule out pregnancy, and - Use at least one method of birth control that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner for the duration of study participation. 8. Willingness not to wash the antecubital lesions on both arms, or the popliteal lesions on both legs, with soap and water from the time of test article application at baseline visit until after the completion of the Day 2 visit. 9. Allow digital photos of arms or legs to be taken and stored. Exclusion Criteria: - 1. Women who are pregnant, planning a pregnancy, or breastfeeding or have a positive pregnancy test at the site. 2. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation. 3. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see Points 5 and 6). 4. Known sensitivity to any of the components of the study medication. 5. Washout of 4 weeks for topical treatments used on the six designated sites, including but not limited to: antibacterial products, anti-inflammatories (e.g. corticosteroids, tacrolimus, Pimecrolimus). Other than the six sites on the arms or legs, topical mediations may be used before/during the duration of the study. 6. Willing not to apply any prescription or over the counter topical product on the selected designated sites on arms or legs. 7. Washout of 4 weeks for systemic treatments for AD, including but not limited to corticosteroids (oral or intramuscular injections), systemic immunomodulators or immunosuppressive (e.g., methotrexate, cyclosporine, hydroxychloroquine), antibiotics (oral or injected, if required to treat a medical condition short duration of oral antibiotics (=10 days) are permitted after randomization). 8. Spontaneously improving or rapidly deteriorating dermatitis of the antecubital fossa or popliteal fossa. 9. Netherton's syndrome or other genodermatoses that result in defective epidermal barrier function. 10. Washout of 4 weeks for bleach baths. 11. Washout of 4 weeks for phototherapy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
J. lividum
Investigational Product

Locations

Country Name City State
Dominican Republic Instituto Dermatologico y Cirugia de Piel Santo Domingo

Sponsors (1)

Lead Sponsor Collaborator
DermBiont, Inc.

Country where clinical trial is conducted

Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Other Atopic Dermatitis signs and symptoms Effect of signs and symptoms of Atopic Dermatitis after a single dose of DBI-001 Gel. • Clinical evaluations will be done by the blinded evaluating investigator of test sites including the Atopic Dermatitis Severity Index (ADSI) and evaluation of erythema, pruritus, exudation, excoriation and lichenification. Scoring: 0+ none (complete absence), 1=slight (slight), 2=moderate (definitely present), 3=severe (marked, intense). 14 Days
Primary Change in Local Tolerability Based on Scale Listed Tolerability will be evaluated through assessment of local signs and symptoms. Scoring for burning, stinging, pruritus, erythema, edema, scabbing or crusting. : 0+ none (complete absence), 1=slight (slight), 2=moderate (definitely present), 3=severe (marked, intense). Baseline (Day 1) and 14
Secondary Change in S. aureus abundance Change in the abundance of S. aureus following a single application of DBI-001 Gel. 14 Days
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2